X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE AUROBINDO PHARMA SUVEN LIFE/
AUROBINDO PHARMA
 
P/E (TTM) x 19.3 14.2 135.5% View Chart
P/BV x 3.6 3.7 97.9% View Chart
Dividend Yield % 1.0 0.4 245.2%  

Financials

 SUVEN LIFE   AUROBINDO PHARMA
EQUITY SHARE DATA
    SUVEN LIFE
Mar-16
AUROBINDO PHARMA
Mar-17
SUVEN LIFE/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs339895 37.8%   
Low Rs144622 23.2%   
Sales per share (Unadj.) Rs39.2254.6 15.4%  
Earnings per share (Unadj.) Rs7.539.3 19.0%  
Cash flow per share (Unadj.) Rs8.846.6 18.8%  
Dividends per share (Unadj.) Rs2.002.50 80.0%  
Dividend yield (eoy) %0.80.3 251.3%  
Book value per share (Unadj.) Rs49.0160.0 30.6%  
Shares outstanding (eoy) m127.28585.88 21.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x6.23.0 206.5%   
Avg P/E ratio x32.419.3 167.6%  
P/CF ratio (eoy) x27.516.3 169.0%  
Price / Book Value ratio x4.94.7 103.9%  
Dividend payout %26.86.4 421.1%   
Avg Mkt Cap Rs m30,732444,390 6.9%   
No. of employees `0001.014.0 6.8%   
Total wages/salary Rs m41617,678 2.4%   
Avg. sales/employee Rs Th5,236.110,667.8 49.1%   
Avg. wages/employee Rs Th436.51,264.3 34.5%   
Avg. net profit/employee Rs Th995.51,645.8 60.5%   
INCOME DATA
Net Sales Rs m4,995149,157 3.3%  
Other income Rs m1941,159 16.7%   
Total revenues Rs m5,189150,316 3.5%   
Gross profit Rs m1,23334,343 3.6%  
Depreciation Rs m1674,276 3.9%   
Interest Rs m54667 8.1%   
Profit before tax Rs m1,20530,558 3.9%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2557,597 3.4%   
Profit after tax Rs m95023,012 4.1%  
Gross profit margin %24.723.0 107.2%  
Effective tax rate %21.224.9 85.1%   
Net profit margin %19.015.4 123.2%  
BALANCE SHEET DATA
Current assets Rs m4,98692,062 5.4%   
Current liabilities Rs m1,04266,223 1.6%   
Net working cap to sales %79.017.3 455.8%  
Current ratio x4.81.4 344.1%  
Inventory Days Days61106 57.5%  
Debtors Days Days3968 57.8%  
Net fixed assets Rs m3,12662,919 5.0%   
Share capital Rs m127586 21.7%   
"Free" reserves Rs m3,71793,133 4.0%   
Net worth Rs m6,23693,719 6.7%   
Long term debt Rs m4321,814 23.8%   
Total assets Rs m8,079162,494 5.0%  
Interest coverage x23.246.8 49.6%   
Debt to equity ratio x0.10 358.1%  
Sales to assets ratio x0.60.9 67.4%   
Return on assets %12.414.6 85.3%  
Return on equity %15.224.6 62.0%  
Return on capital %18.932.7 57.7%  
Exports to sales %87.50-   
Imports to sales %12.20-   
Exports (fob) Rs m4,371NA-   
Imports (cif) Rs m611NA-   
Fx inflow Rs m4,66675,838 6.2%   
Fx outflow Rs m94230,224 3.1%   
Net fx Rs m3,72445,613 8.2%   
CASH FLOW
From Operations Rs m92232,786 2.8%  
From Investments Rs m-619-17,870 3.5%  
From Financial Activity Rs m-698-19,153 3.6%  
Net Cashflow Rs m-396-4,239 9.3%  

Share Holding

Indian Promoters % 63.4 54.1 117.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 8.0 -  
FIIs % 0.0 27.7 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 10.2 357.8%  
Shareholders   37,287 69,601 53.6%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  ALEMBIC LTD  PANACEA BIOTECH  WOCKHARDT LTD.  

Compare SUVEN LIFE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SHARE PRICE


Feb 19, 2018 03:37 PM

TRACK SUVEN LIFE

  • Track your investment in SUVEN LIFE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUVEN LIFE WITH

MARKET STATS